Here, we produce and evaluate HA-displaying CS NPs, using a 180 kDa HA, containing siRNA as an approach to achieving specificity in targeting pancreatic tumor, enhance uptake, and delivering siRNA to knockdown HIF-1α. This evidence concerns the gene HIF1A and pancreatic neoplasm.